EN DE
Watch Enveric Biosciences, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Enveric Biosciences, Inc (ENVB) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Enveric Biosciences, Inc stock $0.77, price $1.44, that is 46.9% below the price, quality 36 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US29405E1091

EB Enveric Biosciences, Inc logo Thin data Nov 14, 2026

Enveric Biosciences, Inc

ENVB · US

Far too expensive (fair value 47% below the price), weak company and price moving sideways: meets none of the 3 rules.

Get notified free when this changes
Price moving sideways (no uptrend) 
Dilution deducted on Oct 30: $0.9000 → $0.7650 
Fair value $0.7650 · Strongly overvalued 
Quality 36/100 
Weak Growth (revenue 3y −6.3 %/yr in USD) 
Negative free cash flow 
Trails peers (2/6) 
Narrow moat 21/100 · thin data
Thin data 
⚠ Dilution
Watch Enveric Biosciences, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$31,500 $1.27 Fair Value $0.7650 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $1.27 – $31,500 · fair‑value band $0.5015 – $0.9520 · the $1.44 price screens above the $0.7650 fair value. As of Nov 14, 2026.

Follow Enveric Biosciences in your weekly email

Every Wednesday you see whether Enveric Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States.

Show moreShow less

Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

The company also develops EVM401 series comprising novel phenylalkylamines and indolethylamines, as well as mescaline-derived compounds to target addiction and neuropsychiatric disorders; and Psybrary, a proprietary library. Enveric Biosciences, Inc. is headquartered in Cambridge, Massachusetts.

Stock analysis

Enveric Biosciences, Inc (ENVB) currently trades at $1.44, while our model-based Fair Value estimate is $0.7650, 47% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.5015 (bear) to $0.9520 (bull), the price of $1.44 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Enveric Biosciences, Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$12.1M in FY2025.

Key figures

Market cap $6.4M Micro · P/S ratio 0.19 · EPS (TTM) $−13.01 · Return on equity −170% · Return on assets (EBIT) −213% (5-year average) · Revenue (TTM) $35.4M · Revenue growth (YoY) −7.3% · Free cash flow −$8.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 86% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −47%, ENVB screens richer than that median.

Fair Value models

Bear $0.5015 Fair Value $0.7650 Bull $0.9520
Price $1.44 · Downside -46.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.5900 $0.9000 $1.12 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.5900 $0.9000 $1.12 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 60
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 23
How calm the share price moves, does not count
Price momentum 19
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.1%
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.6%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.7% (2015) → −14.1% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ENVB screens overvalued: fair value 47% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Enveric Biosciences, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −46.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −7.3% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.54× · Cheaper than median
P/S (12 months) 0.18× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs ENVB
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs ENVB
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs ENVB
argenx SE ARGX $950.95 $908.40 −4% vs ENVB
CSL Limited CSL A$199.55 A$186.49 −7% vs ENVB
Moderna, Inc MRNA $215.27 $135.64 −37% vs ENVB
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs ENVB
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs ENVB
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs ENVB
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs ENVB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Enveric Biosciences, Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Enveric Biosciences, Inc Fair Value". https://www.fairvalue-calculator.com/stock/ENVB

Frequently asked questions

Is Enveric Biosciences, Inc (ENVB) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of $0.7650 versus a price of $1.44, about 47% lower (overvalued).
What is the fair value of ENVB?
Our model-based fair value for Enveric Biosciences, Inc is $0.7650 (as of Nov 14, 2026), built from audited fundamentals. The current price: $1.44.
What is the quality score of ENVB?
Enveric Biosciences, Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Enveric Biosciences, Inc (ENVB)?
Our model-based price target is the fair value of $0.7650 (as of Nov 14, 2026) from 1 valuation models. Cautious scenario $0.5015, optimistic scenario $0.9520. It is a calculation from audited fundamentals, not an analyst target.
What is the Enveric Biosciences, Inc stock forecast for 2026?
Our models put fair value at $0.7650, about 47% lower versus a price of $1.44 (overvalued). Cautious scenario $0.5015, optimistic scenario $0.9520. The calculation is refreshed regularly with new filings.
What is the revenue of Enveric Biosciences, Inc (ENVB)?
Enveric Biosciences, Inc reported trailing-twelve-month revenue of about $35.4M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Enveric Biosciences, Inc (ENVB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Enveric Biosciences, Inc it is $0.7650 per share (as of Nov 14, 2026), against a price of $1.44. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Enveric Biosciences, Inc stock overvalued or undervalued in 2026?
As of Nov 14, 2026, ENVB trades above its calculated fair value: price $1.44, fair value $0.7650, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ENVB?
No. The price is what the market pays today ($1.44); the fair value is what the company's own numbers justify ($0.7650). For Enveric Biosciences, Inc the two are $0.6750 per share apart. That gap is exactly why we show both numbers side by side.
How much is Enveric Biosciences, Inc worth?
The market values Enveric Biosciences, Inc at about $6.4M (market capitalisation, as of Nov 14, 2026). Per share that is $1.44; our models calculate a fair value of $0.7650 per share.
What do the bullish and bearish scenarios say about ENVB?
Our models span a range for Enveric Biosciences, Inc: cautious scenario $0.5015, base $0.7650, optimistic $0.9520 per share (as of Nov 14, 2026, price $1.44). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Enveric Biosciences, Inc (ENVB)?
Balance-sheet figures for Enveric Biosciences, Inc (as of Nov 14, 2026): return on equity −170.0%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is ENVB from its 52-week high?
Enveric Biosciences, Inc trades at $1.44, about 86% below its 52-week high of $10.33 and 13% above the low of $1.27 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7650 is for.
Which stocks are comparable to Enveric Biosciences, Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Enveric Biosciences, Inc stock attractive at the current price?
The data as of Nov 14, 2026: price $1.44, calculated fair value $0.7650 (−47%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ENVB calculated?
We run Enveric Biosciences, Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.7650 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Enveric Biosciences, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Enveric Biosciences, Inc (ENVB)?
The closing price on Nov 16, 2026 was $1.44. Our model-based fair value is $0.7650, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Enveric Biosciences, Inc right now?
The price sits above even our optimistic bull case ($0.9520). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.5015 to $0.9520) leaves room in how you read the outcome.

Key figures of Enveric Biosciences, Inc

How large is the market capitalisation of Enveric Biosciences, Inc (ENVB)?
The market capitalisation of Enveric Biosciences, Inc is $6.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Enveric Biosciences, Inc (ENVB)?
The price-to-sales ratio of Enveric Biosciences, Inc is 0.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Enveric Biosciences, Inc (ENVB)?
Earnings per share at Enveric Biosciences, Inc are $−13.01. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Enveric Biosciences, Inc (ENVB)?
The return on equity (ROE) of Enveric Biosciences, Inc is −170% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Enveric Biosciences, Inc (ENVB)?
On an EBIT basis the return on assets of Enveric Biosciences, Inc is −213% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Enveric Biosciences, Inc (ENVB)?
Revenue at Enveric Biosciences, Inc is down 7.3% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Enveric Biosciences, Inc (ENVB) generate?
The free cash flow of Enveric Biosciences, Inc is −$8.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Enveric Biosciences, Inc (ENVB) hold?
Enveric Biosciences, Inc holds more cash than debt, $4.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Enveric Biosciences, Inc in the live analysis

One click puts Enveric Biosciences, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.